STATEMENT: China Marches into the Era of Direct Interventional Annuloplasty

Launch of the first human “DragonRing” implant: catheter-based mitral annuloplasty device.

STATEMENT: China Marches into the Era of Direct Interventional Annuloplasty

Launch of the first human “DragonRing” implant: catheter-based mitral annuloplasty device

HANGZHOU, China, Nov. 8, 2022 /PRNewswire/ -- On October 28, 2022, an international, multidisciplinary cardiac team led by Professor Mao Chen from the Department of Cardiology, West China Hospital, Sichuan University, successfully performed the world's first human implantation of "DragonRing", which is China's first innovated interventional transfemoral direct annuloplasty ring system that simulates the atrioventricular annuloplasty technology of contemporary cardiac surgery. Fully and independently developed by Hangzhou Valgen Medtech Co., Ltd., DragonRing is designed to effectively treat functional mitral valve regurgitation by dilated annulus strapping, especially targeting the patient population with atrial fibrillation as the primary aetiology of his mitral insufficiency. Professor David Scott Lim, Director of the Advanced Heart Valve Center, University of Virginia, United States; Professor Azeem Latib, Head of Section of Interventional Cardiology, Montefiore Medical Center, United States, and Professor Felix Kreidel, Head of Department of Cardiology, Schleswig-Holstein University, Germany, exchanged techniques together with Professor Mao Chen's team through remote video conferences.

"For functional atrial valve regurgitation, the DragonRing device design aims to replicate the surgical standard of care by reducing annular dilatation, but in a minimally invasive manner, with the advantage of allowing subsequent treatment with other interventional technologies if is needed in the future. This First-in-Human experience is encouraging and we look forward to more data from the subsequent DragonRing study," Professor Scott Lim commented after the procedure.

DragonRing is a novel technology developed to treat valvular regurgitation. Following the successful launches of "DragonFly" (edge-to-edge transcatheter repair system) and "MitralStitch" (transcatheter artificial cord implantation system), Valgen Medtech continues its mission to advance interventional structural cardiac treatment techniques. Valgen is building its reputation with the comprehensive concept of "a toolbox for structural heart disease", with additional innovative products based on "Dragon-" series catheters in its portfolio, offering more options and possible combinations of techniques for practice. future clinical practice, and pushing the limits of interventional treatment of structural heart disease into a new era.

CONTACT: Jiamin Yu, jiamin.yu@valgenmed.com, 86-1

Photo - link

View original content: enlace

Yorum yapabilmek için üye girişi yapmanız gerekmektedir.

Üye değilseniz hemen üye olun veya giriş yapın.

NEXT NEWS